124 related articles for article (PubMed ID: 36540006)
1. Serum miR-146a level is a potential biomarker in predicting the outcome of diffuse large B-cell lymphoma.
Huang X; Gui A; Zhou Y; Xia Z; Liu W; Zuo J; Yang L; Zhang Q
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e283-e290. PubMed ID: 36540006
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
Due H; Schönherz AA; Ryø L; Primo MN; Jespersen DS; Thomsen EA; Roug AS; Xiao M; Tan X; Pang Y; Young KH; Bøgsted M; Mikkelsen JG; Dybkær K
Blood Adv; 2019 Apr; 3(7):1185-1196. PubMed ID: 30967394
[TBL] [Abstract][Full Text] [Related]
4. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
[TBL] [Abstract][Full Text] [Related]
5. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between Serum miR-34a Level and Thrombocytopenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma].
Zhang HL; Uticul A; Xu XW; Shi YW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):784-789. PubMed ID: 35680806
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
8. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
9. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge.
Lavacchi D; Landini I; Perrone G; Roviello G; Mini E; Nobili S
Pharmacol Ther; 2022 Jan; 229():107924. PubMed ID: 34175369
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression.
Ting CY; Tan SY; Gan GG; Zain SM; Pung YF; Ong DB; Bee PC
Int J Lab Hematol; 2022 Oct; 44(5):907-917. PubMed ID: 35830966
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
15. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
18. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
20. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients.
Song G; Gu L; Li J; Tang Z; Liu H; Chen B; Sun X; He B; Pan Y; Wang S; Cho WC
Ann Hematol; 2014 Oct; 93(10):1735-43. PubMed ID: 24858372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]